Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk.
An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick®) (ALA) With Blue Light Model 4170E in the Treatment of Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Located on the Face, Upper Extremities and Trunk.
The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, upper extremities and trunk, using a light sensitive cream used in combination with a light source.
The main questions this trial aims to answer are:
- to confirm using laboratory testing, how much of the affected skin cancer section the treatment was able to remove, and;
- seeing how many participants had no remaining affected skin cancer sections after treatment.
Participants who qualify will be asked to complete 12 visits in total and will receive a total of two treatments, after voluntarily consent has been given.
연구 개요
상태
정황
상세 설명
In the study, participants will be asked to complete the following:
- Provide basic personal information (including date of birth, gender, race and ethnicity)
- Provide their medical/ surgical history and perform a medical exam (including but not limited to physical exam, skin type, vital signs, height, weight and urine pregnancy test collection)
- Follow study rules such as avoiding certain medications and treatments
- Allow photographs of the area of skin cancer being treated on the face or upper extremities/ trunk.
- Provide information on any medications, treatments or reactions that started after the study began
- Allow two treatments on the skin cancer area of the face upper extremities/ trunk using a light sensitive cream used in combination with a light source
- Allow clinical documentation of the treatment, such as how well the treatment was tolerated, any skin reaction or side effects
- Allow surgery to remove the skin cancer area from the face or upper extremities/ trunk for Laboratory testing
To qualify for this trial, participants must:
- be an adult (18 years of age or older)
- give voluntary written consent
- have a recently diagnosed (less than six months from first visit) skin cancer area on the face or upper extremities/ trunk that meets surgery size requirements
- be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
- (if female) not be pregnant before and during the study and agree to use acceptable forms of birth control
- confirm they are not sensitive to any of the study treatment ingredients
All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing.
All photographs of the treatment area collected during the study will be used as study data.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Coordinator
- 전화번호: 305-933-6716
- 이메일: info@centerforclinicalandcosmeticresearch.com
연구 장소
-
-
Florida
-
Aventura, Florida, 미국, 33180
- 모병
- Center for Clinical and Cosmetic Research
-
연락하다:
- Clinical Coordinator
- 전화번호: 305-933-6716
- 이메일: info@centerforclinicalandcosmeticresearch.com
-
수석 연구원:
- Mark S. Nestor, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Must be an adult (18 years of age or older).
- Voluntary written consent required.
- Must have a recently diagnosed (no more than six months from first study visit) facial or trunk/ upper extremities isSCC (Squamous Cell Carcinoma in situ) lesion that meets surgery excision size requirements.
- Cannot have other dermatological disease in the isSCC target area.
- Must be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas.
- If female, cannot be pregnant before and during the study and agree to use acceptable forms of birth control.
Exclusion Criteria:
- Sensitive to any of the study treatment ingredients.
- Pregnant or lactating.
- Medical laboratory evidence of other non-isSCC tumor in the target lesion biopsy specimen.
- History of recurrence in the target isSCC lesion.
- Medical laboratory evidence of certain growth patterns in the target lesion biopsy specimen.
- Chronic medical condition that in the Investigators opinion will interfere in the trial or affect participant safety.
- History of abnormal heart muscles.
- Currently participating in a research study or have been treated with an investigational product within 30 days from first study treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Facial isSCC Photodynamic Therapy (Blue light dose 20 J/cm2)
8 participants will be enrolled to this arm. |
Participants will have their isSCC lesions prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by Blue Light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
다른 이름들:
|
|
실험적: Trunk and/or upper extremities isSCC Photodynamic Therapy (Blue light dose 20 J/cm2)
8 participants will be enrolled to this arm. |
Participants will have their isSCC lesions prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by Blue Light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
다른 이름들:
|
|
실험적: Facial isSCC Photodynamic Therapy (Blue light dose 10 J/cm2)
7 participants will be enrolled to this arm. |
Participants will have their isSCC lesions prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by Blue Light therapy administered for 8 minutes and 20 seconds to deliver the total desired light dose to the isSCC lesion.
다른 이름들:
|
|
실험적: Trunk and/or upper extremities isSCC Photodynamic Therapy (Blue light dose 10 J/cm2)
7 participants will be enrolled to this arm. |
Participants will have their isSCC lesions prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by Blue Light therapy administered for 8 minutes and 20 seconds to deliver the total desired light dose to the isSCC lesion.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with Histological Clearance of treated isSCC lesion
기간: Up to 63 days after treatment 2.
|
Histological clearance is defined as the absence of detectable evidence of isSCC tumor cell nests by the central pathology reports |
Up to 63 days after treatment 2.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with clinical clearance of treated isSCC lesion
기간: Up to 63 days after treatment 2.
|
Complete Clinical Clearance will be measured by the Investigator and is defined as when there is no clinically visible lesion remaining at the site. |
Up to 63 days after treatment 2.
|
|
Local Skin Response Scale
기간: Up to 63 days after treatment 2
|
Observations and changes noted in the aesthetic appearance of the treated isSCC lesion site. |
Up to 63 days after treatment 2
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Mark S Nestor, MD, PhD, Center for Clinical and Cosmetic Research
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CCCR 02-2024
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .